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The use ofprotective agents (e.g., sulfhydryl compounds, certain vitamins, amino acids,
cations, and antibiotics) offers a novel and promising means of dealing with the ever in-
creasing burden of environmental hazards facing man. Through the daily uptake of
minimal doses as a prophylactic measure by the mostendangered groups ofthe population
or by direct mixing ofthe appropriate protective agent with the inducer (e.g., pesticides or
anticancer drugs) it should be possible to reduce or prevent some ofthe most serious toxic
side effects including those of a mutagenic, teratogenic or carcinogenic nature. Among
some of the most outstanding protection examples cited are the antimutagenic, anti-
teratogenic and anticarcinogenic effects of L-cystein, and of some of the vitamins.
However, in view ofour limited understanding ofprotection mechanisms in this fairly new
field of research and due to the toxic side effects of some of the protection agents them-
selves, a large-scale application of this approach cannot be recommended as yet. More
research is urgently needed to study protection mechanisms in suitable standardized
model systems and to develop safer and more efficient protective agents.
Introduction
Now that the negative consequences of in-
dustrialization on the environment have gained
general recognition, more attention should be
devoted to finding practical ways to minimize
effects on present and future generations.
In considering those environmental hazards
which have no useful function, e.g., car exhaust, or
those which can be replaced by less toxic
substitutes, e.g., thalidomide, the necessity for their
elimination should be too obvious for discussion.
The picture is different, however, when we consider
agents having a vital role and which are not readily
replaceable e.g., pesticides and anticancer drugs.
Until less toxic substitutes are found, an effort
should be made to reduce their undesirable side
effects on man. One way to attain this objective
could probably be achieved through the use of pro-
tective agents, i.e., certain compounds such as those
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with SH groups, some vitamins, and amino acids
which, upon application in conjunction with cer-
tain toxic agents, reduce or inhibit their toxic
effects.
Rather than to attempt to cover the whole field,
which has been subject to some excellent recent
reviews on antimutagens (1) and anticarcinogens
(2,3,), the present evaluation will be oriented
mainly to (a) emphasize the universal aspect ofthe
protection phenomenon across several types oftox-
ic effects and different biological systems, (b) dis-
cuss some of the protection mechanisms, and (c)
evaluate the prospects ofusing these agents to cope
with some of today's environmental hazards.
Our present understanding of the mechanisms
involved in the protection activity has not yet
reached the stage which would allow us to recom-
mend the practical use of protective agents at the
present time. This report should, however, serve as
a stimulus for the search for nontoxic )rotective
agents as well as to intensify the study of structure
activity relationships with a view to a better under-
standing of the mechanisms involved.
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"Protection" Phenomenon
There is at present sufficient evidence to prove
that certain chemical agents, including SH com-
pounds, amino acids, vitamins, nucleic acid precur-
sors, cations, and antibiotics, are capable of show-
ing antimutagenic, antiteratogenic and/or anticar-
cinogenic effects if applied in conjunction with the
respective toxic agents. These "protection" effects
are not to be confused with therapy, since both pro-
tector and inducer are applied in these experiments
either simultaneously or within a short time ofeach
other.
The protection phenomenon has some unusual
and fascinating aspects. First, the grave conse-
quences of mutagenesis, teratogenesis, and car-
cinogenesis, normally regarded as irrevocable,
could be inhibited by the mere application of a pro-
tective agent. Second, protection by a given agent is
not specific but is, at least in most cases where suffi-
cient data are available, of a universal nature; a
protector being capable of acting against several
types of inducer in a variety of biological systems
ranging from microorganisms to mammals. It
would certainly be advantageous to develop model
systems, bothin vitro and in vivo, which would per-
mit us to gain a better insight into this universal
aspect of the "anti" activity. The following exam-
ples should serve to demonstrate this universal ac-
tion of protective agents.
SH Compounds
As a representative of this group, we shall consider
L-cystein, one of the best known protective agents.
L-Cystein was shown to protect human cultured
leukocytes against the clastogenic effects of 2,3,5
trisethyleniminobenzoquinone-1,4 (Trenimon) and
busulfan (4), both being alkylating agents, as well
as against 8-oxyquinoline sulfate (5), a nonalkylat-
ing clastogen. Besides this antimutagenic effect, L-
cystein was also found to inhibit the teratogenic
effects of tetramethylthiuram disulfide (Thiram)
(6) as well as the carcinogenic effect of
dibenzanthracene (7).
Vitamins
The anticarcinogenic effects against polycyclic hy-
drocarbons of vitamin A, has been known for
several years (2,8). A 0.5% vitamin A palmitate
diet protected against the effects of 7,12-
dimethylbenz[a]-anthracene (DMBA) (9) in the
induction of cancer of the forestomach and small
intestines as well as dyskeratotic lesions of the
esophagus in Syrian hamsters. In other experi-
ments, 5 mg vitamin A per stomach tube prevented
the appearance ofsquamous metaplasia induced by
an intratrachial application of benzo a pyrene
(BP) in Syrian hamsters (10).
A third example ofthe anticarcinogenic action of
vitamin A could be seen in protection of rhino
mouse skin treated with DMBA after supplementa-
tion of the diet with vitamin A (11).
Riboflavin, another protective vitamin, was also
found to inhibit liver carcinogenesis in rats treated
with 4-dimethylamino-azobenzene (DAB) at a
level of 200 ,ug riboflavin per rat in a diet contain-
ing casein (12). In addition to its anticar-
cinogenicity, riboflavin protected against the
teratogenic effects of both hypoglycine A (13) and
boric acid (14).
Vitamin C made prominent news when it was re-
cently found (15) to prevent the formation of
nitrosamines from amines and nitrites in vitro.
This finding was later confirmed in vivo, a protec-
tive effect of vitamin C having been observed in
rats treated with ethylurea plus sodium nitrite. By
preventing the formation of nitrosoethylurea,
vitamin C protected the treated rats against both
the teratogenic (16) and transplacental car-
cinogenic effects of nitrosoethylurea (17). Since
nitrosamines can be formed in nitrite-treated food
(18) and could also occur in certain pharmaceuti-
cal drugs (19) and because of the mutagenic,
teratogenic, and carcinogenic potential of
nitrosamines (20), there is a good possibility that
vitamin C be considered for use as a protective
agent in endangered foods and drugs.
Amino acids
So far, only a few members of this group have
been shown to have protective effects. L-Glutamic
acid (but notthe D-isomer) was reported to protect
against N-phthalyl-DL-glutamic acid, a teratogenic
metabolite ofthalidomide (21). The observed effect
could not, according to these authors, be simply
due to a compensation for the known glutamic-an-
tagonistic action of the teratogen. L-Asparagine
and,toalesserextent,L-methionineshowedananti-
clastogenic effect against Trenimon in human
lymphocyte cultures (22).
Nucleic Acid Precursors
All four nucleotides TdR, AdR, CdR, and GdR
showed protective effects against lethal mutations
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in addition, an antiteratogenic effect against hy-
droxyurea in rats (24).
Cations
Among the cations showing protective effects,
zinc was found to have both antiteratogenic as well
as anti-carcinogenic potential. Zinc carbonate pro-
tected against EDTA-induced teratogenicity (25),
while zinc acetate proved efficient in countering the
carcinogenic effects of cadmium chloride on the
testes of mice and rats (2).
Sodium cobaltinitrite was also found to protect
mice against skin carcinogenesis induced with
methylcholanthrene (MC) (26).
Trace amounts of cupric oxyacetate in the diet
protected against cancer ofthe liver (but not that of
the skin and ear duct) after treatment with 3-
methoxy-4-aminoazobenzene (27).
Another cation, vanadium, applied in the form
of vanadium pentoxide to the skin of mice treated
with MC prevented the appearance of induced
tumors (28). Finally, Na-fluoride proved to be anti-
mutagenic both in cultured human leukocytes (29)
and in drosophila (30); the cultured cells were pro-
tected against the clastogenic effects of three poly-
functional ethylimines, whereas Drosophila was
protected against mutagenesis by Trenimon and 1-
phenyl-3,3-dimethyltriazine.
Antibiotics
Both chloramphenicol and actinomycin D were
found to have protective effects. Chloramphenicol
protected Drosophila against mutagenesis by x-
rays (31) and showed an anticlastogenic effect
against both cyclophosphamide in HeLa cells (32)
and rubidomycin in bone-marrow cells (33). Its ac-
tivity against carcinogens was also apparent in pro-
tecting rats against cancer induction by the azo
dyes: N-2-fluorenyldiacetamide (34, 35), DAB (36),
and 3'-methyl DAB (37).
Actinomycin D showed an antimutagenic effect
both in yeast (38) andDrosophila (39) as well as an
anticarcinogenic effect against several carcinogenic
hydrocarbons (3).
The above examples, by no means exhaustive,
serve to show that protection is not a specific
phenomenon. The same protective agent is often
capable of countering the damaging effects of
several types of toxic agents in different systems.
This universality of the protective effect, however,
does not apply to the mechanism of protection. A
multiplicity ofmechanisms must be assumed to ex-
plain the protection effects induced by such agents
as cations, nucleic acid precursors and antibiotics,
to mention a few. Even if we consider the protec-
tion mechanism of a single agent, L-cystein, for ex-
ample, we have to conclude that more than one
single mechanism must be at play which would ex-
plain the action of L-cystein against such inducers
as radiation, alkylating and nonalkylating chemi-
cals.
Our present knowledge of the multiplicity of
mechanisms taking part in protection is unfor-
tunately very limited. It would, nevertheless, seem
profitable for our present discussion to point out
some ofthe probable mechanisms playing a part in
the protection effects observed in the examples
cited above.
Mechanism of Protection
It should be possible theoretically, once the
mechanism of action of both inducers and protec-
tors are known, to be able to plan protection
against a given inducer by selecting the optimal
protector and conditions most suited to counter its
action. With our present state of knowledge,
however, we are far from achieving this goal. Suc-
cess in protection experiments is usually achieved
more by trial and error than by design. The reason
for this is the multiplicity of factors playing a role
in the protection phenomenon and which render a
full understanding of the process very difficult to
attain. Among these are: the dose-ratio ofprotector
to inducer; the sequence of application of both
agents; the time lapse between the application of
both agents, the route of application of each agent,
the biological system used, the kinetics of absorp-
tion and activity of each agent, etc. The time lapse
between the application of inducer and protector is
usually very short in protection experiments
against mutagens and teratogens but could extend
over a whole month (the initiative stage) in experi-
ments dealing with carcinogens (2).
There are many possible mechanisms of protec-
tion, including, among others, a direct reaction be-
tween the two agents, an induced decrease in drug
metabolizing activity, competition for binding sites
by the protecting agent, competitive inhibition, and
a stimulation of drug-metabolizing enzymes.
However, stimulation of these enzymes could lead
to protection only if the resultant metabolites are
less active than the intact inducer itself (3). If, on
the other hand, metabolites with a higher activity
are produced through the action of microsomal
enzymes, as is the case with nitrosamines, then an
enhanced toxic activity rather than protection will
result (40). Several agents are known to induce
April 1976 195microsomal enzymes. Among these are several
polycyclic aromatic hydrocarbons; DDT, dieldrin,
barbiturates and others (41). The protective role of
induced enzymes in carcinogenesis has been
reviewed (17, 42). In considering the protective ac-
tion of barbiturates, as one example of an enzyme
inducer, we find that whereas a stimulation of hy-
droxylases seem to explain the protective role of
amylobarbitone against Chlorambucil and
Melphalan (43), a different, and so far an unknown
mechanism, appear to be involved in the protective
effect of phenobarbital against nephrotoxicity in-
duced by methylmercury (44).
Protection could also be mediated by a stimula-
tion ofrepair processes, especially during the labile
mutation fixation period (45). Ifthe protector itself
is mutagenic e.g., chloramphenicol (46) and ac-
tinomycin D (47), then we could expect that part of
the observed protection effect be due to genetic
alterations favoring the appearance of the wild
type e.g., back-mutations, and recombination pro-
cesses.
In the case of anticarcinogens, we could expect,
in addition to the above, that tumor incidence be
reducible through a cytostatic or a cytocidal effect
by the protector on the initiated cells. Another
possibility for protection against the formation of
tumors lies in a stimulation ofthe immune system
by the protector to act against tumor formation.
Antiteratogens could also indirectly act by counter-
ing nonspecific toxic effects of the inducer on the
uterus.
In view of this multiplicity of possible
mechanims, some of which might be operating
simultaneously either synergistically or an-
tagonistically, any attempt at oversimplification in
analyzing the mechanisms involved in a given pro-
tection experiment will be dangerous. It is with this
precaution in mind, that the following discussion
on mechanisms should be considered.
Sulfhydryl Compounds
These "universal" protectors are thought to act
against radiation effects mainly by a scavenging of
radicals (48,49). Their action against the multiple
chemical agents listed above might involve the
stabilization of enzymes through the formation of
enzyme-S-S-protector complexes (50), participa-
tion in repair processes. (51), and others. The exact
mechanism in each case is unknown, however.
Vitamins
Besidestheir knownrole as coenzymes in certain
metabolic reactions, the protective effects observed
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after application of excess amounts suggest other
functions of vitamins applied in conjunction with
the different inducers. A workshop sponsored by
the National Cancer Institute and Hoffmann-La
Roche, Inc. was held recently in Bethesda on the
anticarcinogenic action ofvitamin A (52). The im-
pression gained from the evidence presented by the
participants seems to suggest that a chronic
vitamin A deficiency is associated with an increase
in potency of several carcinogens. The protective
action of added vitamin A was interpreted in one
report as an inhibition of benzo[a]pyrene (BP)
binding to DNA and in another as an inhibition of
BP oxidation (activation) to its presumed car-
cinogenic form. However, the anticarcinogenic
effect of vitamin A was not limited to carcinogens
needing activation. Vitamin A, a known adjuvant,
is also thought to act against carcinogenesis by
stimulating the immune system. Retinyl palmitate
was reported to potentiateby a hundredfold the an-
titumor effect of BCG.
Riboflavin is thought to antagonize the inhibito-
ry effect of hypoglycin A directed against the
acyldehydrogenase flavine-dependent oxidation
reaction (13). Riboflavin-supplementation protects
against azo-dye carcinogenesis, probably by
replenishing the dangerously lowered endogenous
riboflavin level observed in the liver ofrats treated
with DAB (53). This vitamin seems also to play a
role in the activation of microsomal enzymes in-
cluding azo reductases (54).
The protection of vitamin C against the forma-
tion of nitrosamines from their components could
probably be explained by competition of this
vitamin with nitrous acid for combination with the
amines; at least this appeared to be the mechanism
operating in vitro (15). The antiteratogenic effect of
vitamin C against 3-acetylpyrimidine and 6-
aminonictinamide (55) is thought to be mediated
through a stabilization ofmitochondrial structures
attacked by the teratogen.
Amino Acids
L-Asparagine is postulated (22) to protect
human lymphocytes from the clastogenic effect of
Trenimon by stimulating the synthesis of nucleic
acid precursors.
Nucleic Acid Precursors
It can be assumed that, by helping re-establish
DNA and RNA synthesis in cells where this syn-
thesis is inhibited by the inducer, these precursors
could thus offset some ofthe damage induced (24).
Environmental Health PerspectivesCations
The role of various cations in protection can
only be guessed. One possibility is that the small
applied protection dose acts as a catalyst to speed
the breakdown of the inducer to less active compo-
nents (8).
Antibiotics
In the case of protection against N-2-fluorenyl-
diacetamide, chloramphenicol is thought to act by
competing with the carcinogen for certain
enzymatic active sites (35). Some possible explana-
tions of actinomycin D protection mechanisms, are
given in a detailed discussion by Van Duuren and
Melchionne (3).
Protective Agents as a Possible
Tool to Reduce Environmental
Hazards
Even with our present limited knowledge of
mechanisms, there are situations where the use of
protective agents could eventually be envisaged as
a possible means for reducing environmental
hazards. In the following we shall cite some exam-
ples.
As a Prophylactic Measure
Dietary supplements of appropriate protective
agents could possibly protect people working with
genetically active agents. Among these are workers
in oil refineries, in the manufacture ofasbestos, cer-
tain pesticides, PVC, and alkylating agents. Evi-
dence for the carcinogenicity of the last group of
chemicals in man has just been published (56,57).
As a Preventive Measure against
Nitrosamines in Food
The use of vitamin C in this respect is only
justified if its presence does not also protect bac-
teria (especially those ofthe botulinus type) against
the antibiotic effect of nitrite in food. Botulism is
obviously more dangerous than the presence of
traces of nitrosamines.
As a Protector against Side Effects of
Anticancer Therapy
Reducdyn (a combination of N-acetylhemocys-
tein-thilactone, L-cystein, and fructose) is already
being successfully used against the adverse effects
of irradiation (1) and of Trenimon (58). Recently,
thymidine (TdR) was shown to protect against the
toxicity ofmethotrexate while maintaining its anti-
tumor effects in mice bearing leukemia L 1210 (59).
Cysteamine, as well as,/-aminoethyisothiouronium
(AET) showed promise in reducing the clastogenic
effects of the anticancer drug Trenimon without
affecting its cytostatic action in cultured
lymphocytes (60). WIth further research, it should
be possible to reduce the toxic side effects of other
agents used in cancer therapy.
As Protection against the Side Effects
of Antibiotics
Most antibiotics have undesirable side effects,
some of a genetic nature. For example
chloramphenicol is mutagenic in yeast (46) and
teratogenic in the rat (61). Actinomycin D is
mutagenic in the mouse (47) and teratogenic in
Syrian hamsters (62). Gentamicin, mitomycin,
streptonigrin, patulin, phleomycin, and dauno-
mycin induce chromosome abberrations in cultureed
cells (63). It is therefore certainly worth the effort
to find protective agents which would reduce these
side effects without much interference with the
desirable antibiotic action.
As Protection against Side Effects of
Hormones
Any success achieved in this field will be
beneficial not only to patients undergoing hor-
monal therapy (cortisone is a known teratogen;
estrogen is a suspected carcinogen) but to the
millions of women using oral contraceptives, drugs
now suspected of being associated with the ap-
pearance of some hepatomas (64, 65).
As Protection against Other Environ-
mental Hazards
Some promising results show that protection can
be achieved even against air pollution by a dietary
supplement of vitamin E. This was shown in rats
treated with simulated smog (6). Vitamin A was
also cited above as a protector against several car-
cinogens in rats (10). The risks and benefits to man
of these protective agents should be thoroughly in-
vestigated.
In view of the promising aspects of these results
and their possible future use in solving some of to-
day's environmental problems, it is hoped that en-
vironmental agencies encourage more research in
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the mechanisms and the development of effective
protective agents against the environmental
hazards mentioned.
It must be understood, however, that protective
agents known at present offer no panacea, since
many of them have their own undesirable side
effects. the teratogenic and mutagenic effects of
chloramphenicol and actinomycin D have already
been mentioned. Vitamin A, at doses higher than
the daily requirement has long been known to be
both toxic and teratogenic (66, 67). L-Asparagine at
high doses was found to induce brain lesions in
mice (68). NaF increased y-irradiation-induced
recessive lethality in Drosophila (69). A similar
effect in bacteria was observed with zinc chloride
(70). Even L-cystein was capable of increasing
rather than decreasing Thiram-induced lethality in
rats (71). There are also several anticarcinogens
which are themselves carcinogens (3).
Nevertheless, rather than be discouraged by
these difficulties, the promising benefits to man
should encourage us to intensify our efforts to gain
a better understanding of protection mechanisms
by using model systems which permit a systematic
study of structure-activity relationships and to
find better protective agents with less toxic side
effects.
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